RCAMU
BLUE

Rothschild & Co Asset Management US’s bluebird bio BLUE Stock Holding History

Rothschild & Co Asset Management US’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-232
Closed -$438K – 370
2018
Q3 		$438K Hold
232
– – ﹤0.01% 366
2018
Q2 		$471K Sell
232
-2,660
-92% -$6.06M 0.01% 366
2018
Q1 		$6.4M Sell
2,892
-152
-5% -$387K 0.07% 278
2017
Q4 		$7.02M Buy
+3,044
New +$6.18M 0.07% 270

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rothschild & Co Asset Management US's BLUE Position: Q4 2018 in Review

Rothschild & Co Asset Management US sold out of bluebird bio (BLUE) in Q4 2018, closing a stake of 232 shares — an estimated $438K sold.

Rothschild & Co Asset Management US first reported a position in BLUE in Q4 2017 and held it in 4 quarters. The position peaked at $7.02M in Q4 2017. 251 funds tracked by Wall St. Rank hold BLUE as of Q4 2018.

  • Rothschild & Co Asset Management US reported no remaining bluebird bio position as of Q4 2018 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 232 bluebird bio shares in Q4 2018, an estimated $438K.
  • Rothschild & Co Asset Management US first reported a position in bluebird bio in Q4 2017 and held it in 4 quarters.
  • Rothschild & Co Asset Management US's bluebird bio position peaked at $7.02M in Q4 2017.
  • 251 funds tracked by Wall St. Rank held bluebird bio as of Q4 2018.

Based on Rothschild & Co Asset Management US's 13F filing for Q4 2018, filed 5 Feb 2019.